Trials Sponsors Conditions Drugs Pricing

Conditions

Breast Cancer Her 2 Positive Breast Cancer

Keywords

Algerian StudyReal-world dataAlgeriaBiosimilarPertuzumabBreast CancerCancerBreast cancer in Algerian patientsHER2-Positive Breast CancerNeoadjuvant TherapyAnti-HER2 TherapyCohort StudyNon-Interventional StudyHER2-Targeted TherapyObservational Study

Outcome Measures

Primary Outcomes (5)

Treatment Regimen Utilization
Percentage (%) of patients receiving each pertuzumab biosimilar-containing treatment regimen.
Up to 36 months
Line of Therapy
Percentage (%) of patients receiving pertuzumab biosimilar as neoadjuvant therapy or first-line treatment in metastatic setting.
Up to 36 months
Treatment Duration
Median duration of treatment (in months) with pertuzumab biosimilar.
Up to 36 months

Study Arms (2)

Cohort 1

Patients treated with a pertuzumab biosimilar in the neoadjuvant setting for HER2-positive breast cancer.

Cohort 2

Patients treated with a pertuzumab biosimilar as first-line therapy in the metastatic setting for HER2-positive metastatic breast cancer.

Eligibility Criteria

Age19 Years+

Sexfemale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Adult women with HER2-positive breast cancer receiving a pertuzumab biosimilar in the neoadjuvant setting or as first-line treatment in the metastatic setting.

You may qualify if:

Histologically confirmed diagnosis of HER2-positive invasive breast cancer (IHC 3+ score or HER2 amplification by FISH/CISH/SISH);

Sponsors & Collaborators

ES Clinical Research
Type not reportedcollaborator
AlgenPharm
Type not reportedcollaborator
Société Algérienne de Formation et Recherche en Oncologie

Study Sites (2)

CAC BLIDA, Algiers, Algeria 16000

Algiers, Algeria

RECRUITING

BOUNEDJAR Adda, ProfessorCONTACT+213 25 20 90 72 contact@esclinicalresearch.com

CHU Béni Messous, Algiers, Algeria 16000

Algiers, Algeria

RECRUITING

Oukkal Mohammed, ProfessorCONTACT+213 219 311 90

MeSH Terms

Conditions

Breast NeoplasmsNeoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: OTHER
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

April 2, 2026

First Posted

April 21, 2026

Study Start

January 15, 2026

Actual (reported)

Primary Completion

January 15, 2027

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (5)

Study Arms (2)

Cohort 1

Cohort 2

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Design

Study Record Dates

Secondary Outcomes (7)

Other Outcomes (1)

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (5)

Study Arms (2)

Cohort 1

Cohort 2

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Design

Study Record Dates

Secondary Outcomes (7)

Other Outcomes (1)

You may not qualify if:

Data Sharing

Source record

Locations